Transcutaneous tibial nerve stimulation combined mirabegron therapy significantly improves benign prostatic hyperplasia and overactive bladder: a prospective randomized controlled trial
Abstract
OBJECTIVE
To evaluate the efficacy and safety of combining transcutaneous tibial nerve stimulation (TTNS) with mirabegron for treating benign prostatic hyperplasia (BPH) and overactive bladder (OAB) in male patients.
PATIENTS AND METHODS
A total of 62 participants were prospectively randomized into two cohorts: the control group to receive oral mirabegron (50 mg daily), while the combination group to receive combined TTNS and mirabegron. The primary outcomes were changes in voiding frequency and urgency severity, assessed using a 3-day voiding diary. Secondary outcomes included the International Prostate Symptom Score (IPSS), the Overactive Bladder Questionnaire (OAB-q), Health-Related Quality of Life (HRQoL) score, symptom severity, and urodynamic parameters at weeks 6 and 12.
RESULTS
Of the 62 participants, 30 received TTNS along with mirabegron, and 32 received mirabegron alone. At both timepoints, the combination group demonstrated significantly greater reductions in lower urinary tract symptoms (LUTS), including urgency, increased urinary frequency, and incontinence episodes, than the control group (P 0.05).
CONCLUSION
Combined TTNS and mirabegron therapy significantly improved BPH and OAB symptoms and enhanced quality of life, without increasing adverse effects compared to mirabegron monotherapy.
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 62 participants or records.
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.